L.E.K. Consulting

For decades, global medtech has been synonymous with U.S. and European players. That is beginning to change. Chinese medtech companies (and Indian medtech companies too) are increasingly expanding beyond their home market, with Southeast Asia emerging as a key growth battleground. In this conversation with Grace Wang, we discuss what’s driving Chinese progress outside China, and what it means for multinational incumbents as new challengers gain traction across the region. Understanding these dynamics will be critical for both incumbent players and emerging competitors as the next phase of medtech growth unfolds across Asia. https://lnkd.in/g-SDBdgu #Healthcare #China #SoutheastAsia #MedicalTechnology #medtech

India's medtech exports have more than doubled in less than seven years. That’s no fluke: increasingly sophisticated companies with credible technology are building international commercial capabilities which are backed by increasing home market scale and ambitious investors. The question for both OEMs and investors is no longer whether Indian medtechs can compete internationally; it's how to navigate the practical realities of market access, commercial priorities, and in-market execution. #MedTech #India #export #Healthcare #DigitalHealth #PrivateEquity #APAC #LEKHealthcare #StrategyConsulting Shriharsha Sarkar L.E.K. Consulting https://lnkd.in/gGEqd_6x

The #MedTech markets of Asia are growing in importance, and so is the strategic importance of manufacturing and supply chain decisions. Supply chain has moved front and center on the agenda of Exec teams and Boards with increasing implications for market access and commercial success, geopolitics and government affairs, operational risk and resilience, and business growth. #SouthEastAsia offers an expanding range of supply chain configuration options, from wholly owned facilities to increasingly sophisticated contract manufacturing and CDMO partnerships. #SupplyChain #Manufacturing #Healthcare L.E.K. Consulting Grace Wang Wonder Wang https://lnkd.in/g9HH5WZw

Life sciences innovation is no longer centered in just Boston or the Bay Area. Across Asia, innovation hubs are taking shape fast, with China, Korea, Japan and Singapore all building stronger ecosystems. The next question is not whether these hubs are emerging, but how quickly they can mature into globally leading systems. In this video, I share a perspective on what it really takes to build a durable life sciences innovation hub, and where Asian markets still have room to grow. Watch the full video: https://lnkd.in/gZ3ikzy6 @LEK Consulting #LEKConsulting #LifeSciences #AsiaPacific #Biotech #HealthcareInnovation

APAC is one of the fastest-growing pharma regions globally, but it is far from a single, unified market. The region’s complexity creates both opportunities and challenges for biopharma companies looking to scale commercialization across diverse healthcare systems and channels. In this video, I discuss why commercialization platforms are becoming increasingly important across APAC, how they help unlock value across the product life cycle, and why investors are increasingly viewing commercialization capabilities as an investable asset class. We have also published report on this topic, “Going Beyond Distribution: How Commercialization Platforms Are Reshaping Pharma in Asia.” https://lnkd.in/grxqA8SH #LEKConsulting #LifeSciences #Biopharma #APAC #Commercialization #Pharma #PrivateEquity

Every patient in one observational study of insulin self-injection made at least one technique error – in a delivery category patients have used for decades. The most common errors included incorrect injection force (76%), insufficient site rotation (64%) and insufficient dwell time (61%). The implication: making an injection more comfortable is not always enough. Patient-centric design also needs to address a more fundamental source of friction – uncertainty about whether treatment is being administered correctly. Stephen Roper and Edgar Pogna explore how confidence-building features can support correct use, adherence and the value of self-administration. L.E.K. will be at CPHI Milan, Oct. 6–8, 2026. Join us there to discuss what patient-centric drug delivery should look like next. https://lnkd.in/eda8X8Jb